Navigation Links
Rise in Vulvar Precancers Leads to New Guidelines
Date:10/20/2011

THURSDAY, Oct. 20 (HealthDay News) -- The number of American women with precancerous cells of the vulva increased more than fourfold between 1973 and 2000, and the increase has led to the release Thursday of new treatment guidelines by two major medical groups.

Cancer of the vulva -- the outside of the genital area -- is usually caused by infection with human papillomavirus (HPV), which also causes cervical cancer. The precancerous condition -- known as vulvar intraepithelial neoplasia (VIN) -- should be treated with surgery, laser removal or medical therapy, according to the new guidelines from the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology.

VIN is divided into two main types. Usual-type VIN is often associated with cancer-causing strains of HPV and risk factors such as smoking and a weakened immune system. Differentiated VIN is often linked to dermatologic conditions of the vulva.

In most cases of VIN, which is increasingly evident among women in their 40s, there are visible raised lesions that may be white, gray, red, brown or black.

"Most women with VIN will not notice any symptoms, but some may have bleeding, discharge, or itching," Dr. Gerald F. Joseph, Jr., ACOG's vice president for practice activities, said in a college news release.

"It would be sensible for women to periodically examine their vulvar area for any unusual spots or lesions, and if they find something, make an appointment with their ob-gyn," he advised.

While VIN appears to be increasing in the United States, the risk of vulvar cancer is small when compared with cervical, ovarian and uterine cancers, Dr. L. Stewart Massad, a member of ACOG's Committee on Gynecologic Practice, said in the news release.

Much like precancerous cervical lesions, VIN is generally slow-growing, he said. "The quadrivalent HPV vaccine that helps prevent cervical cancer and genital warts has also been shown to decrease the risk of VIN," Massad noted.

Visual examination is the only way to diagnose VIN, and most lesions will need to be biopsied. If cancer is suspected, surgery is the preferred treatment. Laser removal is an acceptable treatment for VIN lesions that appear precancerous. Low-grade lesions can be monitored or treated with a topical cream (5 percent imiquimod) for 12 to 20 weeks, according to the guidelines.

The recurrence rate of VIN is high regardless of the treatment method, and women who've had VIN remain at risk for recurrent VIN and vulvar cancer for the remainder of their lives.

-- Robert Preidt

SOURCE: American College of Obstetricians and Gynecologists, news release, Oct. 20, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Chronic vulvar pain a reality for more than 100,000 women in southeast Michigan
2. Learning Lab of Brentwood Leads Free ADHD Seminar
3. Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeants Pet Care Products, Inc.
4. TechCFO Enters Mid-Atlantic Market; Rick Rolandi Leads DC Metro Office
5. Home Health Agency Owner Pleads Guilty in Connection with Detroit Fraud Scheme
6. New DNA technique leads to a breakthrough in child cancer research
7. AGA leads the way in GI innovation
8. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
9. KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs
10. China's Forbidden City Leads Landmark Climate Action for Earth Hour
11. McMaster researcher leads development of promising drug for inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rise in Vulvar Precancers Leads to New Guidelines  
(Date:6/28/2017)... ... June 28, 2017 , ... ... recognized for excellence in employee engagement. Omaha-based C&A Industries, a national leader ... Most Engaged Workplaces™ in North America for 2017. The annual award, ...
(Date:6/28/2017)... ... 28, 2017 , ... Hayes, Inc., a leading provider of ... speaker lineup* for its second annual Client Symposium. Joining the symposium this year ... Fernandez of Privia Health; and Lisa Tourville of Anthem. , “We are ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... corporate governance program for mid-market executives as a kick-off to the fifth annual ... Sept. 24, 2017 on the University of Pennsylvania campus, followed by the two-day ...
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance ... assistance to clients in southern Montana, is announcing a focused charity effort to ... The outreach programs offered by Zoo Montana provide students with current knowledge on ...
(Date:6/27/2017)... ... 2017 , ... Excel Medical, the leader in Next-Generation Medical ... Executive Vice President, Sales and Marketing. Finnegan is a widely known industry leader ... leadership. He has received industry recognition for innovations and new approaches to sales ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 /PRNewswire/ ... diabetes. In a further effort to help spread lessons ... this condition, the International Diabetes Federation (IDF) and Eli ... come together for the second phase of the Bringing ... (BRIDGES 2), reaffirming their commitment to helping people with ...
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/7/2017)... , June 6, 2017  Diplomat Specialty Infusion Group, a brand ... environment to its Iowa location. ... now features an ISO 7 cleanroom—the standard needed to ... with a low level of pollutants. ... nutrition consumers and better serve our Iowa ...
Breaking Medicine Technology: